Myriad Genetics, Inc. (LON:0K3W)
5.47
0.00 (0.00%)
At close: Jul 7, 2025
Myriad Genetics Revenue
Myriad Genetics had revenue of $195.90M USD in the quarter ending March 31, 2025, a decrease of -3.12%. This brings the company's revenue in the last twelve months to $831.30M, up 7.38% year-over-year. In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth.
Revenue (ttm)
$831.30M
Revenue Growth
+7.38%
P/S Ratio
0.58
Revenue / Employee
$307.89K
Employees
2,700
Market Cap
373.78M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
Jun 30, 2020 | Pro | Pro | Pro |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Myriad Genetics News
- 15 days ago - INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC - GlobeNewsWire
- 5 weeks ago - Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewsWire
- 6 weeks ago - Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - Accesswire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - Accesswire
- 6 weeks ago - Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky - Accesswire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - Accesswire
- 6 weeks ago - Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - Accesswire